| 1 |
Kano Y, Ichikawa H, Hanyu T, Muneoka Y, Ishikawa T, Aizawa M, Matsuki A, Yabusaki H, Bamba T, Nakagawa S, Kobayashi K, Kuwabara S, Makino S, Kawachi Y, Naito T, Tani T, Hirukawa H, Tada T, Shimada Y, Sakata J, Wakai T. Conversion surgery for stage IV gastric cancer: a multicenter retrospective study. BMC Surg 2022;22:428. [DOI: 10.1186/s12893-022-01874-8] [Reference Citation Analysis]
|
| 2 |
Kano Y, Ichikawa H, Hanyu T, Muneoka Y, Ishikawa T, Aizawa M, Matsuki A, Yabusaki H, Bamba T, Nakagawa S, Kobayashi K, Kuwabara S, Makino S, Kawachi Y, Naito T, Tani T, Hirukawa H, Tada T, Shimada Y, Sakata J, Wakai T. Conversion surgery for stage IV gastric cancer: a multicenter retrospective study.. [DOI: 10.21203/rs.3.rs-2070683/v1] [Reference Citation Analysis]
|
| 3 |
Yu D, Wang Z, He T, Yang L. Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study. Front Surg 2022;9:842828. [DOI: 10.3389/fsurg.2022.842828] [Reference Citation Analysis]
|
| 4 |
Marrelli D, Rosa F, Bagnacci G, Defraia C. Therapeutic Approach to cT4b Gastric Cancer. Gastric Cancer: the 25-year R-Evolution 2022. [DOI: 10.1007/978-3-030-73158-8_17] [Reference Citation Analysis]
|
| 5 |
Ye Z, Zeng Y, Wei S, Wang Y, Lin Z, Chen S, Wang Z, Chen S, Chen L. Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer. BMC Cancer 2021;21:702. [PMID: 34126957 DOI: 10.1186/s12885-021-08459-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Huang C, Hu C, Zhu J, Zhang W, Huang J, Zhu Z. Establishment of Decision Rules and Risk Assessment Model for Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer. Front Oncol 2020;10:1638. [PMID: 32984033 DOI: 10.3389/fonc.2020.01638] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 7 |
Yeh YS, Huang MY, Ma CJ, Huang CW, Tsai HL, Chen YC, Li CC, Yu FJ, Shih HY, Wang JY. Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. J Oncol 2020;2020:6931317. [PMID: 32963531 DOI: 10.1155/2020/6931317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Jeong GS, Lee IS, Park YS, Kim BS, Yoo MW, Yook JH, Kim BS. Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers. J Gastric Cancer 2020;20:233-44. [PMID: 33024580 DOI: 10.5230/jgc.2020.20.e20] [Reference Citation Analysis]
|
| 9 |
Maeda O, Ando Y. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World J Gastrointest Oncol 2019; 11(7): 518-526 [PMID: 31367271 DOI: 10.4251/wjgo.v11.i7.518] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 10 |
Su Z, Shu K, Kang M, Wang G. Pathological complete response from oral chemotherapy combined with trans-arterial chemotherapy and embolization in an unresectable gastric cancer patient: A case report. Medicine (Baltimore) 2019;98:e16075. [PMID: 31232946 DOI: 10.1097/MD.0000000000016075] [Reference Citation Analysis]
|
| 11 |
Park JH, Yang JY, Park YH, Lee WK. The long-term prognostic difference between gastrectomy with and without preoperative chemotherapy in patients with clinical stage IV gastric cancer. Asian J Surg 2019;42:922-9. [PMID: 30685146 DOI: 10.1016/j.asjsur.2019.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Liu FL, Zhao NQ, Liu TS. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget 2016;7:76298-307. [PMID: 27602586 DOI: 10.18632/oncotarget.11818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 13 |
Park K, Jang G, Baek S, Song H. Usefulness of Combined PET/CT to Assess Regional Lymph Node Involvement in Gastric Cancer. Tumori 2014;100:201-6. [DOI: 10.1177/030089161410000214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 14 |
Joo I, Kim SH, Ahn SJ, Lee ES, Shin CI, Lee HJ, Yang HK. Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria. Abdom Radiol (NY) 2017;42:2807-15. [PMID: 28643135 DOI: 10.1007/s00261-017-1224-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Jung YJ, Seo HS, Kim JH, Park CH, Lee HH. Cross-Sectional Location of Gastric Cancer Affects the Long-Term Survival of Patients as Tumor Invasion Deepens. Ann Surg Oncol 2017;24:3947-53. [PMID: 28980179 DOI: 10.1245/s10434-017-6101-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Kataoka K, Deleersnijder A, Lordick F. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol. 2017;43:1835-1845. [PMID: 28888797 DOI: 10.1016/j.ejso.2017.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Li Y, Chen J, He Q, Ji X, Wang X, Fan C, Li G. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis. Oncotarget 2017;8:86886-96. [PMID: 29156843 DOI: 10.18632/oncotarget.19004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. 2018;50:518-529. [PMID: 28546521 DOI: 10.4143/crt.2017.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 19 |
Villaverde RM, Gordo AJ, del Moral ASJ, Álvarez-mon Soto M. Cáncer de estómago. Medicine - Programa de Formación Médica Continuada Acreditado 2017;12:1904-1910. [DOI: 10.1016/j.med.2017.04.011] [Reference Citation Analysis]
|
| 20 |
Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, Komori S, Yoshida T, Tanabe S, Koizumi W, Katada N, Watanabe M. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today 2017;47:1249-58. [PMID: 28365892 DOI: 10.1007/s00595-017-1512-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 21 |
Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, Park SR, Yook JH, Oh ST, Yoo MW, Kim BS, Kang YK. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer. Gastric Cancer 2017;20:182-9. [PMID: 26661592 DOI: 10.1007/s10120-015-0580-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 23 |
Dassen AE, Bernards N, Lemmens VE, Wouw YAV, Bosscha K, Creemers GJ, Pruijt HJ. Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg 2016; 8(10): 706-712 [PMID: 27830043 DOI: 10.4240/wjgs.v8.i10.706] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 24 |
Ma J, Yao S, Li XS, Kang HR, Yao FF, Du N. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study. Medicine (Baltimore) 2015;94:e1489. [PMID: 26496252 DOI: 10.1097/MD.0000000000001489] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Ma LG, Xi HQ, Chen L. Conversion therapy for unresectable gastric cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(4): 528-534 [DOI: 10.11569/wcjd.v24.i4.528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 26 |
Jung JT. Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Korean J Gastroenterol 2016;68:234. [DOI: 10.4166/kjg.2016.68.5.234] [Reference Citation Analysis]
|
| 27 |
Kinoshita O, Ichikawa D, Ichijo Y, Komatsu S, Okamoto K, Kishimoto M, Yanagisawa A, Otsuji E. Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. World J Gastroenterol 2015; 21(48): 13500-13506 [PMID: 26730161 DOI: 10.3748/wjg.v21.i48.13500] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Koo DH, Ryu MH, Ryoo BY, Seo J, Lee MY, Chang HM, Lee JL, Lee SS, Kim TW, Kang YK. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. Gastric Cancer 2015;18:346-53. [PMID: 24832201 DOI: 10.1007/s10120-014-0385-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 29 |
Phua VCE, Wong WQ, Tan PL, Bustam AZ, Saad M, Alip A, Ishak WZW. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice. Asian Pacific Journal of Cancer Prevention 2015;16:1449-1453. [DOI: 10.7314/apjcp.2015.16.4.1449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 30 |
Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol 2014;74:1139-47. [DOI: 10.1007/s00280-014-2586-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 31 |
Wei ZW, Li JL, Wu Y, Xia GK, Schwarz RE, He YL, Zhang CH. Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study. Dig Dis Sci 2014;59:1017-24. [PMID: 24318804 DOI: 10.1007/s10620-013-2965-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 32 |
An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB, Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J. 2013;54:888-894. [PMID: 23709422 DOI: 10.3349/ymj.2013.54.4.888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 33 |
Gunderson LL, Donohue JH, Alberts SR, Ashman JB, Jaroszewski DE. Cancer of the Stomach and Gastroesophageal Junction. Abeloff's Clinical Oncology 2014. [DOI: 10.1016/b978-1-4557-2865-7.00075-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 34 |
Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535-e547. [PMID: 24176572 DOI: 10.1016/s1470-2045(13)70436-4] [Cited by in Crossref: 326] [Cited by in F6Publishing: 354] [Article Influence: 32.6] [Reference Citation Analysis]
|
| 35 |
Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013;30:119-29. [PMID: 23867588 DOI: 10.1159/000350877] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 36 |
Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol 2013;28:777-82. [PMID: 23425049 DOI: 10.1111/jgh.12152] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Son SY, Lee CM, Lee JH, Ahn SH, Kim JW, Lee KU, Park do J, Kim HH. Laparoscopy-assisted gastrectomy with para-aortic lymphadenectomy after palliative chemotherapy for advanced gastric cancer with isolated para-aortic lymph node metastasis. J Korean Surg Soc. 2013;84:304-308. [PMID: 23646317 DOI: 10.4174/jkss.2013.84.5.304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013;108:519-526. [PMID: 23322206 DOI: 10.1038/bjc.2012.588] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 39 |
Han DS, Suh YS, Kong SH, Lee HJ, Im SA, Bang YJ, Kim WH, Yang HK. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol 2013;107:511-6. [PMID: 23090791 DOI: 10.1002/jso.23284] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 40 |
Thuss-Patience PC, Hofheinz RD, Arnold D, Florschütz A, Daum S, Kretzschmar A, Mantovani-Löffler L, Bichev D, Breithaupt K, Kneba M. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Ann Oncol. 2012;23:2827-2834. [PMID: 22734012 DOI: 10.1093/annonc/mds129] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 41 |
An JY, Kim KM, Kim YM, Cheong JH, Hyung WJ, Noh SH. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. Ann Surg Oncol. 2012;19:2452-2458. [PMID: 22395984 DOI: 10.1245/s10434-012-2267-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 42 |
Sato T, Rino Y, Yamada R, Oshima T, Masuda M. Neoadjuvant Chemotherapy of Resectable Advanced Gastric Cancer. JJCS 2012;37:197-204. [DOI: 10.4030/jjcs.37.197] [Reference Citation Analysis]
|
| 43 |
Mahvi DM, Krantz SB. Stomach. Sabiston Textbook of Surgery 2012. [DOI: 10.1016/b978-1-4377-1560-6.00049-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 44 |
Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, Chang HM, Lee JL, Kim TW, Kang YK. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol 2011;68:913-21. [PMID: 21290247 DOI: 10.1007/s00280-011-1561-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 45 |
Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, Kim BS, Kim TW. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2011;67:1435-1443. [PMID: 20811894 DOI: 10.1007/s00280-010-1444-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 46 |
Inno A, Basso M, Cassano A, Barone C. A Review of Docetaxel: Its Use in the Treatment of Gastric Cancer. Clinical Medicine Insights: Therapeutics 2010;2:CMT.S5191. [DOI: 10.4137/cmt.s5191] [Reference Citation Analysis]
|
| 47 |
Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol. 2010;66:721-728. [PMID: 20041328 DOI: 10.1007/s00280-009-1215-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
|
